Cargando…
Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment
Epithelial-mesenchymal transition (EMT), a differentiation process with aberrant changes of tumor cells, is identified as an initial and vital procedure for metastatic processes. Inflammation is a significant inducer of EMT and provides an indispensable target for blocking EMT, however, an anti-infl...
Autores principales: | Jiang, Tianze, Xie, Laozhi, Zhou, Songlei, Liu, Yipu, Huang, Yukun, Mei, Ni, Ma, Fenfen, Gong, Jingru, Gao, Xiaoling, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429706/ https://www.ncbi.nlm.nih.gov/pubmed/36045429 http://dx.doi.org/10.1186/s12951-022-01592-6 |
Ejemplares similares
-
Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
por: Zhou, Songlei, et al.
Publicado: (2023) -
Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2012) -
Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer
por: Wu, Sheng-Mao, et al.
Publicado: (2022) -
Histone deacetylase 6 inhibition counteracts the epithelial–mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis
por: Xu, Liuqing, et al.
Publicado: (2017) -
Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells
por: Shi, Yingfeng, et al.
Publicado: (2021)